Study guide
13.5 Calcium Regulation & Hypercalcaemia
MRCP UK
Track your progress as you read
Finished sections get a check mark.
1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy
1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique
2 Clinical Sciences: Cellular, Genetic & Molecular Medicine
2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders
3 Clinical Sciences: Anatomy, Physiology & Immunology
3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions
4 Clinical Sciences: Statistics, Epidemiology & Trial Design
4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification
5 Clinical Pharmacology, Therapeutics & Toxicology
5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols
6 Cardiology: Coronary Artery Disease & Heart Failure
6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation
7 Cardiology: Arrhythmias, Valvular & Pericardial Disease
7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases
8 Respiratory Medicine: Airway & Parenchymal Lung Disease
8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis
9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders
9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing
10 Gastroenterology: Luminal Gastrointestinal Disease
10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia
11 Gastroenterology: Liver, Biliary & Pancreatic Disease
11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis
12 Endocrinology & Diabetes: Diabetes & Thyroid
12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules
13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium
13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease
14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease
14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases
15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance
15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis
16 Neurology: Cerebrovascular, Headache & Demyelinating Disease
16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases
17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease
17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders
18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease
18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies
19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy
19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease
20 Infectious Diseases & Tropical Medicine
20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites
21 Haematology: Anaemias & Red Cell Disorders
21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease
22 Haematology: Malignancy, Coagulation & Transfusion Medicine
22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions
23 Psychiatry in General Medicine
23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law
24 Geriatric Medicine
24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers
25 Dermatology
25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy
26 Oncology & Palliative Medicine
26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control
27 Medical Ophthalmology
27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease
13.5 Calcium Regulation & Hypercalcaemia
Key Takeaways Explain This Topic AI
Corrected calcium adds 0.02 mmol/L for every 1 g/L that albumin falls below 40 g/L.
A raised or inappropriately normal PTH with hypercalcaemia indicates primary hyperparathyroidism or familial hypocalciuric hypercalcaemia, which is separated by a low urinary calcium:creatinine clearance ratio.
Hypercalcaemia of malignancy is treated with vigorous intravenous saline rehydration followed by intravenous bisphosphonate, which takes 2-4 days to act.
Last updated: September 2026
Extracellular calcium is vital for neuromuscular transmission, myocardial excitation-contraction coupling, blood coagulation, and skeletal mineralization. The parathyroid glands, kidneys, skeleton, and gastrointestinal tract interact via parathyroid hormone (PTH), calcitriol, and fibroblast growth factor 23 (FGF23) to maintain ionized calcium within a narrow physiological window. Mastery of calcium emergencies and metabolic bone disorders is central to MRCP(UK) Part 1.
- 1. Calcium Regulation & Corrected Calcium
- Fractional Calcium & The Albumin Correction Formula
Circulating total serum calcium comprises three distinct physicochemical fractions:
Ionized Calcium ( ∼ 45 – 50 % \sim 45\text{–}50\% ∼ 45 – 50% ): The biologically active, strictly regulated fraction.
Protein-Bound Calcium ( ∼ 40 – 45 % \sim 40\text{–}45\% ∼ 40 – 45% ): Bound predominantly to albumin ( ∼ 80 % \sim 80\% ∼ 80% ) and globulins ( ∼ 20 % \sim 20\% ∼ 20% ).
Complexed Calcium ( ∼ 10 % \sim 10\% ∼ 10% ): Chelation complexes with citrate, phosphate, and bicarbonate.
Because total calcium fluctuates with alterations in serum albumin, laboratories report adjusted (corrected) calcium : Corrected Calcium (mmol/L) = Total Calcium (mmol/L) + 0.02 × ( 40 − Serum Albumin [g/L] ) \text{Corrected Calcium (mmol/L)} = \text{Total Calcium (mmol/L)} + 0.02 \times \big(40 - \text{Serum Albumin [g/L]}\big) Corrected Calcium (mmol/L) = Total Calcium (mmol/L) + 0.02 × ( 40 − Serum Albumin [g/L] )
MRCP Acid-Base Pearl: Systemic pH alters ionized calcium without changing total calcium. Acidosis displaces calcium from albumin binding sites, increasing free ionized calcium. Conversely, acute alkalosis (e.g. hyperventilation / panic attack) increases negative charges on albumin, driving calcium binding and triggering acute hypocalcaemic tetany and carpopedal spasm despite a completely normal total serum calcium.
Hormonal Control of Calcium & Phosphate
Parathyroid Hormone (PTH): An 84-amino-acid peptide secreted by parathyroid chief cells in response to reduced ionized calcium sensed by cell-surface G-protein coupled calcium-sensing receptors (CaSR) . Actions:
Bone: Stimulates osteoblast expression of RANKL , which binds RANK on osteoclast precursors, activating osteoclastic bone resorption and releasing calcium and phosphate.
Kidney: Increases distal convoluted tubule calcium reabsorption (via TRPV5 channels); downregulates NaPi-2a/NaPi-2c cotransporters in the proximal tubule to promote phosphaturia ; and stimulates renal 1 α 1\alpha 1 α -hydroxylase ( C Y P 27 B 1 CYP27B1 C Y P 27 B 1 ) to convert 25-hydroxyvitamin D into active 1 , 25 1,25 1 , 25 -dihydroxyvitamin D3 (calcitriol).
Net Effect: ↑ Serum Calcium \uparrow \text{Serum Calcium} ↑ Serum Calcium , ↓ Serum Phosphate \downarrow \text{Serum Phosphate} ↓ Serum Phosphate , ↑ Urinary Phosphate \uparrow \text{Urinary Phosphate} ↑ Urinary Phosphate , ↑ Calcitriol \uparrow \text{Calcitriol} ↑ Calcitriol .
Calcitriol ( 1 , 25 -(OH) 2 -D 3 1,25\text{-(OH)}_2\text{-D}_3 1 , 25 -(OH) 2 -D 3 ): Steroid hormone synthesized in the renal proximal tubule. Binds nuclear vitamin D receptors (VDR), upregulating intestinal calbindin-D9k and epithelial calcium channels (TRPV6) to dramatically increase intestinal absorption of both calcium and phosphate . Net effect: ↑ Serum Calcium \uparrow \text{Serum Calcium} ↑ Serum Calcium , ↑ Serum Phosphate \uparrow \text{Serum Phosphate} ↑ Serum Phosphate .
Fibroblast Growth Factor 23 (FGF23): Secreted by osteocytes in response to hyperphosphataemia. Binds FGFR1/Klotho complexes in the proximal tubule to induce massive phosphaturia and inhibit 1 α 1\alpha 1 α -hydroxylase, preventing hyperphosphataemia.
2. Hypercalcaemia: Etiology, Differential & Crisis Protocols
More than 90 % 90\% 90% of all hypercalcaemic cases are attributable to either Primary Hyperparathyroidism (most common in outpatients) or Malignancy (most common in hospitalized patients).
Primary Hyperparathyroidism (PHPT)
Etiology: Autonomous parathyroid oversecretion caused by a single solitary parathyroid adenoma (80–85%) , four-gland primary hyperplasia ( 15 % 15\% 15% , frequently linked to MEN1 or MEN2A), or parathyroid carcinoma ( < 1 % < 1\% < 1% ).
Clinical Presentation: Classically remembered as 'stones, bones, abdominal groans, and psychiatric moans' :
Stones: Nephrolithiasis (calcium oxalate/phosphate stones in 15 – 20 % 15\text{–}20\% 15 – 20% ) and nephrocalcinosis.
Bones: Bone pain, osteopenia/osteoporosis (predominantly cortical bone loss at the distal radius), and severe subperiosteal bone resorption ( osteitis fibrosa cystica , brown tumors, and 'salt-and-pepper' skull).
Abdominal Groans: Constipation, anorexia, nausea, peptic ulcer disease (calcium stimulates gastrin secretion), and acute pancreatitis (calcium activates pancreatic trypsinogen).
Psychiatric Moans: Depression, cognitive slowing, fatigue, and psychosis.
Biochemical Profile: Elevated corrected calcium, low or low-normal serum phosphate, elevated or inappropriately normal intact PTH (in the setting of hypercalcaemia, any detectable PTH > 1.5 – 2.0 pmol/L > 1.5\text{–}2.0\text{ pmol/L} > 1.5 – 2.0 pmol/L is pathologically inappropriate), elevated alkaline phosphatase (in high-turnover bone disease), and elevated 24-hour urinary calcium excretion .
Pre-operative Localization: Technetium-99m sestamibi SPECT-CT scan and high-resolution neck ultrasonography.
Surgical Indications (Parathyroidectomy): Symptomatic disease, or asymptomatic patients meeting any NICE/international consensus criterion:
Age < 50 < 50 < 50 years
Serum adjusted calcium > 0.25 mmol/L > 0.25\text{ mmol/L} > 0.25 mmol/L above upper reference limit ( > 2.85 mmol/L > 2.85\text{ mmol/L} > 2.85 mmol/L )
T-score ≤ − 2.5 \le -2.5 ≤ − 2.5 at lumbar spine, total hip, femoral neck, or distal radius, or previous fragility fracture
Estimated GFR < 60 mL/min/1.73 m 2 < 60\text{ mL/min/1.73 m}^2 < 60 mL/min/1.73 m 2 or nephrolithiasis/nephrocalcinosis on imaging
24-hour urinary calcium excretion > 10 mmol/day > 10\text{ mmol/day} > 10 mmol/day ( > 400 mg/day > 400\text{ mg/day} > 400 mg/day )
Familial Hypocalciuric Hypercalcaemia (FHH)
Genetics & Pathophysiology: Autosomal dominant condition caused by heterozygous inactivating mutations in the calcium-sensing receptor gene ( CaSR ) on chromosome 3q. The mutated parathyroid and renal CaSRs perceive normal calcium concentrations as hypocalcaemic; the set-point for calcium-mediated PTH suppression is shifted upward. Patients exhibit lifelong, benign, asymptomatic mild hypercalcaemia with normal or mildly elevated PTH.
Distinction from PHPT: In FHH, renal tubular calcium reabsorption is abnormally elevated despite hypercalcaemia, leading to profound hypocalciuria . The diagnostic differentiator is the Calcium-to-Creatinine Clearance Ratio (CCCR) : CCCR = Urinary Calcium [mmol/L] × Serum Creatinine [umol/L] Serum Calcium [mmol/L] × Urinary Creatinine [umol/L] \text{CCCR} = \frac{\text{Urinary Calcium [mmol/L]} \times \text{Serum Creatinine [umol/L]}}{\text{Serum Calcium [mmol/L]} \times \text{Urinary Creatinine [umol/L]}} CCCR = Serum Calcium [mmol/L] × Urinary Creatinine [umol/L] Urinary Calcium [mmol/L] × Serum Creatinine [umol/L]
CCCR < 0.01 \text{CCCR} < 0.01 CCCR < 0.01 ( < 1 % < 1\% < 1% ): Highly diagnostic of Familial Hypocalciuric Hypercalcaemia (FHH) . Parathyroidectomy is completely ineffective and strictly contraindicated! Reassure the patient and perform cascade family screening.
CCCR > 0.02 \text{CCCR} > 0.02 CCCR > 0.02 ( > 2 % > 2\% > 2% ): Confirms Primary Hyperparathyroidism .
CCCR 0.01 – 0.02 \text{CCCR } 0.01\text{–}0.02 CCCR 0.01 – 0.02 : Indeterminate grey zone; requires genetic testing for CaSR mutations.
Hypercalcaemia of Malignancy
Malignancy causes rapid, symptomatic hypercalcaemia through three principal mechanisms:
Humoral Hypercalcaemia of Malignancy (HHM, ~80%): Secretion of PTH-related protein (PTHrP) by solid tumors, particularly squamous cell carcinomas (lung, head and neck, oesophagus), renal cell carcinoma, and breast cancer. PTHrP binds the common PTH1 receptor, stimulating osteolysis and renal calcium reabsorption: corrected calcium is elevated, phosphate is low, PTHrP is elevated, but intact PTH is completely suppressed ( < 1.0 pmol/L < 1.0\text{ pmol/L} < 1.0 pmol/L ) .
Local Osteolytic Hypercalcaemia (~20%): Extensive bone metastases or haematological malignancy ( multiple myeloma , breast carcinoma) release local osteoclast-activating cytokines (IL-1, IL-6, TNF- α \alpha α , RANKL). PTH is suppressed.
1 α 1\alpha 1 α -Hydroxylase Overproduction ( < 1 % < 1\% < 1% ): Unregulated extra-renal conversion of 25-OH-D to calcitriol by tumor-associated macrophages in Hodgkin and non-Hodgkin lymphomas (and non-malignant granulomatous diseases: sarcoidosis , tuberculosis). Both calcium and phosphate are elevated; PTH is suppressed.
Emergency Management of Acute Hypercalcaemic Crisis
Severe hypercalcaemia (corrected calcium > 3.5 mmol/L > 3.5\text{ mmol/L} > 3.5 mmol/L ) or hypercalcaemic crisis (polyuria, dehydration, delirium, cardiac arrhythmias, shortened QTc) is a medical emergency:
Aggressive Fluid Resuscitation (First-Line): Infuse intravenous 0.9% normal saline at 3 to 4 liters per 24 hours ( 200 – 300 mL/hour 200\text{–}300\text{ mL/hour} 200 – 300 mL/hour titrated to cardiovascular status and urine output). Re-expands profound intravascular volume depletion, restores GFR, and promotes proximal tubular calcium excretion. (Loop diuretics such as furosemide are strictly restricted to patients developing fluid overload/pulmonary oedema ; they are no longer used routinely due to worsening dehydration).
Intravenous Bisphosphonates (Second-Line): Following initial hydration, administer intravenous Zoledronic acid (4 mg over 15 minutes) or pamidronate ( 60 – 90 mg 60\text{–}90\text{ mg} 60 – 90 mg ). Inhibits osteoclastic farnesyl pyrophosphate synthase, halting bone resorption. Onset of action takes 48 to 72 hours, with nadir calcium achieved at 4 to 7 days. Dose reduction required in severe renal impairment.
Calcitonin: Subcutaneous or IM salmon calcitonin ( 4 – 8 IU/kg 4\text{–}8\text{ IU/kg} 4 – 8 IU/kg 12-hourly). Provides rapid onset ( 2 – 4 hours 2\text{–}4\text{ hours} 2 – 4 hours ) of calcium reduction by promoting renal excretion and inhibiting osteoclasts, serving as an acute bridge while awaiting bisphosphonate effect. Efficacy is limited by tachyphylaxis (receptor downregulation) within 48 hours .
Refractory or Renal Failure Cases: Denosumab (monoclonal antibody targeting RANKL; 120 mg 120\text{ mg} 120 mg SC) is highly effective for bisphosphonate-refractory hypercalcaemia and safe in advanced chronic kidney disease. Glucocorticoids (oral prednisolone 30–60 mg daily) are specifically effective in lymphoma, sarcoidosis, and vitamin D toxicity by suppressing macrophage 1 α 1\alpha 1 α -hydroxylase activity. Emergency low-calcium haemodialysis is reserved for refractory hypercalcaemia complicated by acute oliguric renal failure.